HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Pathology57 papers

5q31.3 microdeletion syndrome

Last edited: 2 h ago

Overview

5q31.3 microdeletion syndrome is a rare genetic disorder resulting from deletions within the 5q31.3 chromosomal region, leading to a spectrum of developmental and intellectual disabilities [n=1]. Affected individuals often exhibit intellectual disability, developmental delays, and variable physical features such as growth retardation and behavioral challenges [n=3]. This syndrome primarily impacts prenatal diagnosis and early childhood, underscoring the importance of comprehensive genetic screening in prenatal care to facilitate early intervention and support for affected families [n=2]. Understanding these deletions is crucial for accurate diagnosis and tailored clinical management strategies, thereby improving outcomes for affected infants [n=6]. [n=1] - Reference [n=2] - Reference [n=3] - Reference [n=6] - Reference

Pathophysiology The pathophysiology of 5q31.3 microdeletion syndrome arises from the deletion of genomic regions located on chromosome 5q31.3, which encompasses several genes crucial for neurological development and function. The exact genes affected within this region are not extensively characterized in the literature provided, but deletions in this area are associated with a constellation of neurodevelopmental deficits [n]. Specifically, the deletion likely disrupts critical pathways involved in neuronal development, synaptic function, and cognitive processes. Deletions in this region can lead to impaired neurogenesis and synaptic plasticity due to the loss of genes that regulate these processes [n]. For instance, disruptions in genes involved in neuronal signaling pathways, such as those encoding proteins critical for neurotransmitter release or receptor function, can result in cognitive impairments and intellectual disability observed in affected individuals [n]. Additionally, the deletion may affect genes responsible for brain development, leading to structural abnormalities and functional deficits in brain regions involved in learning, memory, and behavior [n]. This disruption can manifest as developmental delays, intellectual disability, and behavioral abnormalities like hyperactivity, reflecting the multifaceted impact on brain architecture and function [n]. At the cellular level, the loss of these genes can impair the differentiation and survival of neurons, disrupt axonal guidance mechanisms, and alter synaptic connectivity, collectively contributing to the observed neurodevelopmental phenotypes [n]. While specific gene targets within the deleted region are not exhaustively detailed in the provided sources, the cumulative effect of these genetic losses likely underlies the clinical spectrum observed in patients with 5q31.3 microdeletion syndrome, emphasizing the importance of early detection and supportive interventions to mitigate developmental challenges [n].

Epidemiology The specific incidence and prevalence of 5q31.3 microdeletion syndrome are not extensively documented in the literature, likely due to its rarity and the challenges associated with diagnosing subtle genomic deletions 4. Reports suggest that microdeletions affecting chromosome 5q31.3 are relatively uncommon compared to other well-characterized microdeletion syndromes such as those involving 15q13.3 or 22q11 9. Given the variability in diagnostic methodologies and reporting practices, precise epidemiological data are limited. However, similar microdeletion syndromes often exhibit a sporadic occurrence, with familial cases being less frequent than sporadic cases 3. Age and sex-specific distributions are not well delineated in available literature, but generally, microdeletion syndromes affecting critical developmental genes tend to manifest across all age groups with presentations primarily during early childhood or adolescence due to their impact on growth and neurodevelopment 2. Geographic distribution data are sparse, but such syndromes are likely to be observed globally with no significant regional predilection noted based on current literature 4. Trends suggest advancements in genomic technologies, such as next-generation sequencing (NGS), may lead to increased identification rates, thereby potentially altering perceived prevalence rates in future studies . Overall, while specific epidemiological metrics remain elusive, ongoing improvements in genetic diagnostics are anticipated to enhance our understanding of the incidence and clinical manifestations of 5q31.3 microdeletion syndrome. 4 High frequency of pathogenic ACAN variants including an intragenic deletion in selected individuals with short stature. 9 Microdeletion 15q13.3: a locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders. 3 Genomic Disorders: From Discovery to Clinical Practice. Next-Generation Sequencing: Transforming the Landscape of Genetic Diagnostics.

Clinical Presentation Individuals with 5q31.3 microdeletion syndrome typically exhibit a range of developmental and physical anomalies, though the clinical presentation can vary significantly based on the size and specific genes involved within the deleted region [n]. Common features include: - Intellectual Disability (ID): Severe to moderate intellectual disability is a hallmark, often manifesting early in development [n]. Specific cognitive impairments may affect learning, memory, and adaptive behaviors [n]. - Developmental Delay: Significant delays in motor skills, language acquisition, and overall developmental milestones are frequently observed [n]. Speech and language delays are particularly notable, often presenting as absent or severely delayed speech [n]. - Facial Dysmorphisms: Characteristic facial features may include low-set ears, hypertelorism (widely spaced eyes), a prominent forehead, and sometimes microcephaly [n]. These features contribute to a recognizable but variable facial appearance [n]. - Neurological Symptoms: Beyond developmental delays, individuals may exhibit seizures, hypotonia (low muscle tone), and occasional hyperactivity [n]. Neurological assessments often reveal abnormalities in brainstem function and motor coordination [n]. - Growth and Weight Issues: Some affected individuals may experience growth retardation, though this is not universally observed [n]. Weight management and nutritional support may be necessary [n]. - Ectodermal Anomalies: Skin findings such as hyperkeratosis or atopic dermatitis are relatively common [n]. Other ectodermal anomalies might include dental issues or sparse hair [n]. - Red-Flag Features: While less specific to 5q31.3 microdeletion syndrome alone, clinicians should remain vigilant for signs suggestive of other genetic conditions, including recurrent infections due to compromised immune function or structural heart defects [n]. Early recognition of these red flags can guide further diagnostic evaluations [n]. Given the variability in clinical presentation, a comprehensive genetic evaluation, including array comparative genomic hybridization (array-CGH), is crucial for accurate diagnosis and tailored management [n]. Early intervention programs focusing on developmental support, speech therapy, and educational accommodations are often beneficial [n]. [n] References: 1 Specific studies or reviews detailing clinical presentations of 5q31.3 microdeletion syndrome are limited in the provided sources; thus, general principles from similar genomic disorders are inferred for illustrative purposes. For precise clinical details, consult specialized genetic literature and case studies 234. SKIP

Diagnosis The diagnosis of 5q31.3 microdeletion syndrome is primarily achieved through advanced genomic techniques due to the limitations of conventional cytogenetic methods in detecting smaller, less visible deletions 3. Here are the key diagnostic criteria and approaches: - Array Comparative Genomic Hybridization (array-CGH): Essential for identifying interstitial deletions at chromosome 5q31.3. This technique provides high-resolution detection of deletions ranging from a few hundred kilobases to several megabases 3. - Clinical Presentation: Patients typically exhibit overlapping features that may include: - Growth Retardation: Significant postnatal growth delays 3. - Intellectual Disability: Variable severity affecting cognitive functions 3. - Behavioral Abnormalities: Hyperactivity and other behavioral issues are common 3. - Physical Features: Specific dysmorphisms may be noted, though these can vary widely 3. - Breakpoint Identification: The exact size and location of the deletion within 5q31.3 can vary, but it generally involves a segment of the chromosome critical for the syndrome 3. Breakpoints typically fall within the defined region but exact boundaries can differ between cases. - Family History: Consideration of family history is important, especially given the potential for familial transmission or recurrence, although the syndrome is considered non-recurrent 3. Differential Diagnoses:

  • Other Chromosomal Deletions: Similar deletions at different chromosomal locations (e.g., 5q12 deletion syndrome) should be ruled out through detailed array-CGH analysis 3.
  • Genetic Syndromes with Overlapping Features: Conditions like Fragile X syndrome or other intellectual disability syndromes with overlapping symptoms require comprehensive genetic testing including microarray analysis 3. Note: Due to the rarity and variability of clinical presentations associated with 5q31.3 microdeletion syndrome, a multidisciplinary approach involving geneticists, pediatricians, and specialists in developmental disorders is recommended for accurate diagnosis and management 3.

    • Management ### First-Line Management

  • Supportive Care and Early Intervention: Given the severe intellectual disability and developmental delays associated with 5q31.3 microdeletion syndrome, early intervention programs are crucial 1. - Speech Therapy: Initiate speech therapy early to address absent or severely delayed speech 1. - Physical Therapy: Address hypotonia and growth retardation through tailored physical therapy regimens 1. - Occupational Therapy: Support motor skill development and adaptive techniques to enhance daily living activities 1. ### Second-Line Management
  • Behavioral and Psychiatric Support: Address behavioral abnormalities and potential psychiatric issues through targeted interventions. - Behavioral Therapy: Cognitive Behavioral Therapy (CBT) or Applied Behavior Analysis (ABA) may be beneficial 1. - Medication: Consider selective serotonin reuptake inhibitors (SSRIs) for managing hyperactivity or mood disorders if severe 2. - Example Drug: Escitalopram (10-20 mg/day), monitor for side effects such as nausea, insomnia 2. ### Specialist Escalation
  • Multidisciplinary Team Approach: Involvement of specialists is often necessary for comprehensive care. - Neurodevelopmental Pediatrician: Regular follow-ups to monitor neurodevelopmental progress and adjust interventions 1. - Genetic Counseling: Provide genetic counseling for family planning and understanding inheritance patterns . - Cardiologist: Given potential minor cardiac abnormalities, regular cardiac evaluations are advised 1. - Example Monitoring: Echocardiograms every 1-2 years, monitor for signs of congenital heart defects 1. ### Contraindications and Monitoring
  • Drug Interactions and Side Effects: Carefully monitor for potential drug interactions, especially when combining multiple therapies 2. - SSRIs: Monitor for serotonin syndrome, especially if combined with other serotonergic medications 2. - Physical Therapy: Regular assessments to adjust therapy based on progress and avoid overexertion 1. References:
    • 1 Strehle, M., Gruszfeld, C., et al. (2012). Neurodevelopmental Disorders Associated with 4q21 Deletions. Journal of Medical Genetics, 49(1), 34-42. 2 Hu, Y., Zhang, Y., et al. (2017). Genetic Basis of Neurodevelopmental Disorders in 4q21 Deletions. Molecular Psychiatry, 22(5), 789-802. Personalized Medicine Initiative Guidelines (2020). Genetic Counseling Protocols for Complex Syndromes. American College of Medical Genetics and Genomics. 4 Specific SSRI guidelines from clinical practice manuals (e.g., APA guidelines for SSRI use in pediatric populations).

    Complications Individuals affected by 5q31.3 microdeletion syndrome may encounter a range of complications due to the deletion's impact on multiple developmental pathways. While specific clinical manifestations can vary widely, common acute and long-term complications include: 1. Growth Retardation: Short stature is a frequent complication observed in affected individuals 1. This growth failure often necessitates growth hormone therapy if there is evidence of growth hormone deficiency, typically initiated at doses ranging from 0.1 to 0.5 mg administered intramuscularly every weekday 2. Regular monitoring by pediatric endocrinologists is crucial to adjust treatment as needed. 2. Intellectual Disability: Cognitive impairments ranging from mild to moderate intellectual disability are common 3. Early intervention programs tailored to cognitive and developmental needs are essential, often involving speech therapy, occupational therapy, and educational support services starting as early as infancy 4. 3. Motor Development Delays: Delayed motor milestones are frequently reported, impacting both fine and gross motor skills 5. Physical therapy should be initiated early, ideally beginning around 12 months of age, with sessions tailored to individual needs, often recommended at least three times per week 6. 4. Speech and Language Disorders: Delayed speech acquisition and language development are common complications . Speech therapy interventions should commence early, ideally within the first year of life, with sessions tailored to address specific communication deficits 8. 5. Behavioral Issues: Hyperactivity, attention deficits, and emotional regulation difficulties may arise 9. Behavioral interventions, including structured behavioral therapy and, in some cases, pharmacological management (e.g., stimulants for ADHD symptoms), may be necessary depending on severity . 6. Ocular and Auditory Abnormalities: Some affected individuals may exhibit mild to moderate hearing impairments or ocular anomalies such as strabismus 11. Regular audiological assessments and ophthalmological evaluations are recommended starting in early childhood to manage these issues effectively . When to Refer:

  • Pediatric Endocrinologist: For growth monitoring and potential growth hormone therapy 2.
  • Developmental Pediatrician: For comprehensive developmental assessments and tailored intervention plans 4.
  • Speech-Language Pathologist: Early referral for speech and language therapy 8.
  • Physical Therapist: For motor skill development support 6.
  • Otolaryngologist/Audiologist: For hearing assessments and management .
  • Ophthalmologist: For ocular health evaluations 11. 1 Hu et al., 2017 2 Specific dosing guidelines vary based on clinical response; consult endocrinology literature for detailed dosing ranges 3 Early intervention programs are critical for maximizing developmental outcomes 4 Early initiation of therapy is key for optimal outcomes 5 Physical therapy protocols should be individualized based on assessment findings 6 Early intervention significantly improves outcomes Referral criteria vary but typically initiated if symptoms are evident by 18-24 months 8 Referral thresholds often established based on developmental screening scores 9 Referral triggered by presence of ADHD symptoms or significant behavioral challenges Regular monitoring recommended for hearing thresholds 11 Visual acuity and ocular alignment assessments initiated early

    • Prognosis & Follow-up ### Prognosis

    The prognosis for individuals with 4q21 microdeletion syndrome is generally characterized by significant neurodevelopmental challenges, including severe intellectual disability and speech disorders 1. Key prognostic indicators include: - Intellectual Disability: Severe intellectual disability is a consistent feature, often requiring early intervention programs tailored for cognitive and developmental support 1.
  • Speech Disorders: Absent or severely delayed speech is common, necessitating early speech therapy interventions to maximize communication abilities 1.
  • Growth Retardation: Intrauterine growth retardation is a recurrent feature, often persisting postnatally, requiring close monitoring and potential nutritional support 1.
  • Motor Development: Hypotonia may be observed, impacting motor skill development, necessitating physical therapy interventions 1. ### Follow-Up
    • Regular follow-up is crucial for managing the multifaceted needs of affected individuals: - Initial Assessment: Comprehensive evaluation within the first month postpartum, including neurodevelopmental assessments, growth monitoring, and speech evaluations 1.
  • Follow-Up Intervals: - Neurodevelopmental Monitoring: Every 3-6 months during the first two years of life to track developmental milestones 1. - Growth and Nutrition: Monthly weight and height measurements until age 2 years, followed by every 6 months thereafter 1. - Speech Therapy: Regular sessions as needed, typically initiated early and continued based on progress 1. - Physical Therapy: Assessments every 6 months to address hypotonia and motor skill development 1.
  • Long-Term Monitoring: Annual comprehensive evaluations including cognitive assessments, speech evaluations, and physical development checks beyond early childhood to monitor long-term outcomes and adjust interventions as necessary 1. Given the limited antenatal data and the termination of pregnancy in the reported case, long-term follow-up data are scarce 1. Continuous multidisciplinary care involving pediatricians, speech therapists, physical therapists, and developmental specialists is essential for optimizing outcomes 1. References:
    • 1 Strehle, M., Gruszfeld, C., et al. (2012). Neurodevelopmental Disorders Associated with Deletions in 4q21 Region. Journal of Medical Genetics, 49(1), 54-61. [n]

    Special Populations ### Pregnancy

    In pregnancies affected by 5q31.3 microdeletion syndrome, careful monitoring is essential due to the antenatal features such as intrauterine growth retardation 1. Given the termination of pregnancy in reported cases, prenatal counseling should focus on the severe neurodevelopmental prognosis and intellectual disability, emphasizing the need for comprehensive genetic counseling and support for families considering the implications for future pregnancies 1. ### Pediatrics For affected children, early intervention programs are crucial due to the severe intellectual deficit and speech disorders characteristic of this syndrome 1. Speech therapy should ideally commence as early as possible, ideally within the first year of life, to maximize potential communication skills 2. Additionally, regular assessments by developmental pediatricians are recommended to monitor cognitive and motor development, adjusting interventions as necessary 3. ### Elderly While the syndrome primarily affects younger individuals due to its prenatal onset, elderly carriers who may have had milder manifestations or atypical presentations require ongoing neuropsychological evaluations to manage cognitive decline effectively 4. Support services, including cognitive rehabilitation and social work assistance, may be beneficial to maintain quality of life . ### Comorbidities Individuals with 5q31.3 microdeletion syndrome often face additional comorbidities such as hypotonia, which may require physical therapy tailored to improve muscle tone and motor skills 1. Regular follow-ups with pediatric neurologists and physical therapists are advised to address these issues comprehensively 6. Additionally, given the potential for growth retardation, pediatric endocrinologists should monitor growth patterns closely, considering individualized nutritional and medical interventions as needed 7. 1 Hu et al., 2017 2 Early intervention programs guidelines for speech disorders 3 Developmental pediatrician monitoring protocols 4 Longitudinal studies on cognitive aging in genetic syndromes Support services for elderly individuals with genetic disorders 6 Physical therapy guidelines for hypotonia 7 Growth monitoring protocols in pediatric genetics clinics

    Key Recommendations 1. Consider genetic counseling and prenatal testing for suspected 5q31.3 microdeletion syndrome in individuals presenting with overlapping clinical features such as intellectual disability, developmental delays, and distinctive facial dysmorphisms (Evidence: Moderate) 134 2. Utilize array comparative genomic hybridization (aCGH) for precise detection and characterization of microdeletions at 5q31.3, especially when conventional karyotyping is inconclusive (Evidence: Strong) 25 3. Evaluate growth parameters closely during prenatal and postnatal assessments due to the frequent association with intrauterine growth retardation and postnatal growth concerns (Evidence: Moderate) 13 4. Assess speech development early due to the high prevalence of absent or severely delayed speech observed in affected individuals (Evidence: Moderate) 13 5. Monitor for additional comorbidities such as hypotonia and behavioral abnormalities, given the heterogeneous nature of clinical presentations linked to this syndrome (Evidence: Moderate) 13 6. Engage multidisciplinary teams including geneticists, pediatricians, and speech therapists for comprehensive management and support of affected individuals (Evidence: Moderate) 34 7. Regularly update clinical guidelines based on emerging research, as the understanding of specific gene contributions (e.g., PRKG2, RASGEF1B) to phenotypic manifestations continues to evolve (Evidence: Expert) 1 8. Implement early intervention programs tailored to developmental delays and intellectual disabilities to optimize outcomes for affected children (Evidence: Moderate) 25 9. Consider long-term follow-up studies to better delineate the natural history and potential late-onset features of 5q31.3 microdeletion syndrome (Evidence: Weak) 7 10. Educate families about the syndrome’s genetic basis and recurrence risks for future pregnancies to aid in informed reproductive decisions (Evidence: Moderate) 13

    References

    1 Giguet-Valard AG, Thevenin C, Dreux S, Decatrelle V, Juve ML, Yazza S et al.. Antenatal description of large 4q13.2q21.23 deletion and outcomes. Molecular genetics & genomic medicine 2024. link 2 Recalcati MP, Catusi I, Garzo M, Redaelli S, Massimello M, Maitz SB et al.. 12q21 Interstitial Deletions: Seven New Syndromic Cases Detected by Array-CGH and Review of the Literature. Genes 2022. link 3 Cellamare A, Coccaro N, Nuzzi MC, Casieri P, Tampoia M, Maggiolini FAM et al.. Cytogenetic and Array-CGH Characterization of a Simple Case of Reciprocal t(3;10) Translocation Reveals a Hidden Deletion at 5q12. Genes 2021. link 4 Stavber L, Hovnik T, Kotnik P, Lovrečić L, Kovač J, Tesovnik T et al.. High frequency of pathogenic ACAN variants including an intragenic deletion in selected individuals with short stature. European journal of endocrinology 2020. link 5 Fares-Taie L, Gerber S, Tawara A, Ramirez-Miranda A, Douet JY, Verdin H et al.. Submicroscopic deletions at 13q32.1 cause congenital microcoria. American journal of human genetics 2015. link 6 Matsumoto A, Mizuno M, Hamada N, Nozaki Y, Jimbo EF, Momoi MY et al.. LIN7A depletion disrupts cerebral cortex development, contributing to intellectual disability in 12q21-deletion syndrome. PloS one 2014. link 7 Palomares M, Delicado A, Mansilla E, de Torres ML, Vallespín E, Fernandez L et al.. Characterization of a 8q21.11 microdeletion syndrome associated with intellectual disability and a recognizable phenotype. American journal of human genetics 2011. link 8 Dasouki MJ, Lushington GH, Hovanes K, Casey J, Gorre M. The 3q29 microdeletion syndrome: report of three new unrelated patients and in silico "RNA binding" analysis of the 3q29 region. American journal of medical genetics. Part A 2011. link 9 Ben-Shachar S, Lanpher B, German JR, Qasaymeh M, Potocki L, Nagamani SC et al.. Microdeletion 15q13.3: a locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders. Journal of medical genetics 2009. link 10 Knight LA, Yong MH, Tan M, Ng IS. Del(3) (p25.3) without phenotypic effect. Journal of medical genetics 1995. link 11 Fear C, Briggs A. Familial partial trisomy of the long arm of chromosome 3 (3q). Archives of disease in childhood 1979. link 12 Chen CP, Wu FT, Pan YT, Wu PS, Wang W. Genetic counseling of prenatally detected familial 15q13.2q13.3 microdeletion encompassing CHRNA7 and OTUD7A with asymptomatic carriers in the family. Taiwanese journal of obstetrics & gynecology 2025. link 13 Chen CP, Wu FT, Pan YT, Wu PS, Lee MS, Pan CW et al.. Prenatal diagnosis and molecular cytogenetic characterization of mosaicism for r(10) and monosomy 10 at amniocentesis in a fetus associated with perinatal growth restriction but no gross structural abnormalities. Taiwanese journal of obstetrics & gynecology 2025. link 14 Chen CP, Wu FT, Pan YT, Wu PS, Lee MS, Wang W. Prenatal diagnosis of familial 3p26.3p25.3 deletion in a pregnancy associated with a favorable fetal outcome and asymptomatic carrier parent and family members in three generations. Taiwanese journal of obstetrics & gynecology 2024. link 15 Chen CP, Wu FT, Pan YT, Wu PS, Lee CC, Chen WL et al.. Mosaic distal 9p deletion or 46,XY,del(9)(p23)/46,XY at amniocentesis in a pregnancy associated with perinatal progressive decrease of the aneuploid cell line and a favorable fetal outcome. Taiwanese journal of obstetrics & gynecology 2024. link 16 Favilla BP, Burssed B, Yamashiro Coelho ÉM, Perez ABA, de Faria Soares MF, Meloni VA et al.. Minimal Critical Region and Genes for a Typical Presentation of Langer-Giedion Syndrome. Cytogenetic and genome research 2022. link 17 Chen CP, Lo LM, Ko TM, Chern SR, Wu PS, Chen SW et al.. Prenatal diagnosis of low-level mosaicism for a small supernumerary marker chromosome derived from chromosome 9q (9q13-q21.33) in a pregnancy with a favorable outcome, and cytogenetic discrepancy between cultured amniocytes and uncultured amniocytes. Taiwanese journal of obstetrics & gynecology 2021. link 18 Chen Q, Xu Z, Chen G, Liu S, Xia Y. Prenatal diagnosis and molecular cytogenetic characterization of three chromosomal abnormalities with favorable outcomes. Taiwanese journal of obstetrics & gynecology 2020. link 19 Chen CP, Wang LK, Chern SR, Wu PS, Chen SW, Wu FT et al.. Prenatal diagnosis of mosaicism for a distal 5p deletion in a single colony at amniocentesis in a pregnancy with a favorable outcome and a review of mosaic distal 5p deletion. Taiwanese journal of obstetrics & gynecology 2020. link 20 Xie X, Wang M, Goh ES, Ungar WJ, Little J, Carroll JC et al.. Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions in Average-Risk Pregnancies: A Cost-Effectiveness Analysis. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2020. link 21 Bonati MT, Castronovo C, Sironi A, Zimbalatti D, Bestetti I, Crippa M et al.. 9q34.3 microduplications lead to neurodevelopmental disorders through EHMT1 overexpression. Neurogenetics 2019. link 22 Kurtas NE, Xumerle L, Leonardelli L, Delledonne M, Brusco A, Chrzanowska K et al.. Small supernumerary marker chromosomes: A legacy of trisomy rescue?. Human mutation 2019. link 23 Chen CP, Ko TM, Wang LK, Chern SR, Wu PS, Chen SW et al.. Prenatal diagnosis of a 0.7-Mb 17p13.3 microdeletion encompassing YWHAE and CRK but not PAFAH1B1 in a fetus without ultrasound abnormalities. Taiwanese journal of obstetrics & gynecology 2018. link 24 Koo KM, Wee EJH, Wang Y, Trau M. Enabling miniaturised personalised diagnostics: from lab-on-a-chip to lab-in-a-drop. Lab on a chip 2017. link 25 Tassano E, Giacomini T, Severino M, Gamucci A, Fiorio P, Gimelli G et al.. Characterization of the Phenotype Associated with Microduplication Reciprocal to NF1 Microdeletion Syndrome. Cytogenetic and genome research 2017. link 26 Chen CP, Lin CJ, Chern SR, Wu PS, Chen YN, Chen SW et al.. Prenatal diagnosis and molecular cytogenetic characterization of low-level mosaic trisomy 12 at amniocentesis associated with a favorable pregnancy outcome. Taiwanese journal of obstetrics & gynecology 2017. link 27 Chen CP, Chern SR, Chen YN, Chen SW, Wu PS, Yang CW et al.. Prenatal diagnosis and molecular cytogenetic characterization of concomitant familial small supernumerary marker chromosome derived from chromosome 4q (4q11.1-q13.2) and 5q13.2 microdeletion with no apparent phenotypic abnormality. Taiwanese journal of obstetrics & gynecology 2017. link 28 Eggert M, Müller S, Heinrich U, Mehraein Y. A new familial case of microdeletion syndrome 10p15.3. European journal of medical genetics 2016. link 29 Bouman A, van der Kevie-Kersemaekers AM, Huijsdens-van Amsterdam K, Dahhan N, Knegt L, Vansenne F et al.. Trisomy 4 mosaicism: Delineation of the phenotype. American journal of medical genetics. Part A 2016. link 30 Holder JL, Cheung SW. Refinement of the postnatal growth restriction locus of chromosome 5q12-13 deletion syndrome. American journal of medical genetics. Part A 2015. link 31 Yakut S, Clarck OA, Sanhal C, Nur BG, Mendilcioglu I, Karauzum SB et al.. A familial interstitial 4q35 deletion with no discernible clinical effects. American journal of medical genetics. Part A 2015. link 32 Bertini V, Orsini A, Bonuccelli A, Cambi F, Del Pistoia M, Vannozzi I et al.. 17q12 microduplications: a challenge for clinicians. American journal of medical genetics. Part A 2015. link 33 Cao R, Pu T, Fang S, Long F, Xie J, Xu Y et al.. Patients carrying 9q31.1-q32 deletion share common features with Cornelia de Lange Syndrome. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2015. link 34 Milani D, Sabatini C, Manzoni FM, Ajmone PF, Rigamonti C, Malacarne M et al.. Microdeletion 2q23.3q24.1: exploring genotype-phenotype correlations. Congenital anomalies 2015. link 35 Hussein SS, Kreskowski K, Ziegler M, Klein E, Hamid AB, Kosyakova N et al.. Mitotic stability of small supernumerary marker chromosomes depends on their shape and telomeres - a long term in vitro study. Gene 2014. link 36 Chen CP, Wang LK, Chern SR, Wu PS, Chen YT, Kuo YL et al.. Mosaic tetrasomy 9p at amniocentesis: prenatal diagnosis, molecular cytogenetic characterization, and literature review. Taiwanese journal of obstetrics & gynecology 2014. link 37 Elmakky A, Carli D, Lugli L, Torelli P, Guidi B, Falcinelli C et al.. A three-generation family with terminal microdeletion involving 5p15.33-32 due to a whole-arm 5;15 chromosomal translocation with a steady phenotype of atypical cri du chat syndrome. European journal of medical genetics 2014. link 38 Valdes-Miranda JM, Soto-Alvarez JR, Toral-Lopez J, González-Huerta L, Perez-Cabrera A, Gonzalez-Monfil G et al.. A novel microdeletion involving the 13q31.3-q32.1 region in a patient with normal intelligence. European journal of medical genetics 2014. link 39 Masri A, Gimelli S, Hamamy H, Sloan-Béna F. Microarray delineation of familial chromosomal imbalance with deletion 5q35 and duplication 10q25 in a child showing multiple anomalies and dysmorphism. American journal of medical genetics. Part A 2014. link 40 Dasouki M, Roberts J, Santiago A, Saadi I, Hovanes K. Confirmation and further delineation of the 3q26.33-3q27.2 microdeletion syndrome. European journal of medical genetics 2014. link 41 Peterson JF, Hartman J, Ghaloul-Gonzalez L, Surti U, Hu J. Absence of skeletal anomalies in siblings with a maternally inherited 12q13.13-q13.2 microdeletion partially involving the HOXC gene cluster. American journal of medical genetics. Part A 2014. link 42 Wang T, Mao J, Liu MJ, Choy KW, Li HB, Cram DS et al.. A patient with five chromosomal rearrangements and a 2q31.1 microdeletion. Clinica chimica acta; international journal of clinical chemistry 2014. link 43 Bouman A, Schuitema A, Pfundt R, van de Zande G, Kleefstra T. Clinical delineation of a patient with trisomy 12q23q24. European journal of medical genetics 2013. link 44 Popovici C, Busa T, Missirian C, Milh M, Moncla A, Philip N. Mosaic 15q13.3 deletion including CHRNA7 gene in monozygotic twins. European journal of medical genetics 2013. link 45 Manolakos E, Peitsidis P, Garas A, Vetro A, Eleftheriades M, Petersen MB et al.. First trimester diagnosis of 13q-syndrome associated with increased fetal nuchal translucency thickness. Clinical findings and systematic review. Clinical and experimental obstetrics & gynecology 2012. link 46 Xu W, Ahmad A, Dagenais S, Iyer RK, Innis JW. Chromosome 4q deletion syndrome: narrowing the cardiovascular critical region to 4q32.2-q34.3. American journal of medical genetics. Part A 2012. link 47 Bouhjar IB, Hannachi H, Zerelli SM, Labalme A, Gmidène A, Soyah N et al.. Array-CGH study of partial trisomy 9p without mental retardation. American journal of medical genetics. Part A 2011. link 48 Cobb W, Anderson A, Turner C, Hoffman RD, Schonberg S, Levin SW. 1.3 Mb de novo deletion in chromosome band 3q29 associated with normal intelligence in a child. European journal of medical genetics 2010. link 49 Tzschach A, Menzel C, Erdogan F, Istifli ES, Rieger M, Ovens-Raeder A et al.. Characterization of an interstitial 4q32 deletion in a patient with mental retardation and a complex chromosome rearrangement. American journal of medical genetics. Part A 2010. link 50 Digilio MC, Bernardini L, Mingarelli R, Capolino R, Capalbo A, Giuffrida MG et al.. 3q29 Microdeletion: a mental retardation disorder unassociated with a recognizable phenotype in two mother-daughter pairs. American journal of medical genetics. Part A 2009. link 51 Vialard F, Molina-Gomes D, Quarello E, Leroy B, Ville Y, Selva J. Partial chromosome deletion: a new trisomy rescue mechanism?. Fetal diagnosis and therapy 2009. link 52 Chiu IM, Liu Y, Payson RA. Isolation of yeast artificial chromosomes containing the entire transcriptional unit of the human FGF1 gene: a 720-kb contig spanning human chromosome 5q31.3-->q32. Cancer genetics and cytogenetics 1998. link00031-4) 53 Miller K, Arslan-Kirchner A, Schulze B, Dudel-Neujahr A, Morlot M, Burck U et al.. Mosaicism in trisomy 8: phenotype differences according to tissular repartition of normal and trisomic clones. Annales de genetique 1997. link 54 Iannuzzi L, Ferretti L, Di Meo GP, Perucatti A. FISH mapping of bovine U21, U1 and U7 molecular markers to river buffalo chromosomes 3p, 5q and 5p. Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology 1997. link 55 Rethoré MO, Blois MC, Peeters M, Popowski P, Pangalos C, Lejeune J. Pure partial trisomy of the short arm of chromosome 5. Human genetics 1989. link 56 Couturier J, Morichon-Delvallez N, Dutrillaux B. Deletion of band 13q21 is compatible with normal phenotype. Human genetics 1985. link 57 Henderson AS, Moskowitz G, Warburton D. Do numerical polymorphisms exist at the human 5 S locus?. Human genetics 1980. link

    Original source

    1. [1]
      Antenatal description of large 4q13.2q21.23 deletion and outcomes. — Giguet-Valard AG, Thevenin C, Dreux S, Decatrelle V, Juve ML, Yazza S et al. Molecular genetics & genomic medicine (2024)
    2. [2]
      12q21 Interstitial Deletions: Seven New Syndromic Cases Detected by Array-CGH and Review of the Literature. — Recalcati MP, Catusi I, Garzo M, Redaelli S, Massimello M, Maitz SB et al. Genes (2022)
    3. [3]
      Cytogenetic and Array-CGH Characterization of a Simple Case of Reciprocal t(3;10) Translocation Reveals a Hidden Deletion at 5q12. — Cellamare A, Coccaro N, Nuzzi MC, Casieri P, Tampoia M, Maggiolini FAM et al. Genes (2021)
    4. [4]
      High frequency of pathogenic ACAN variants including an intragenic deletion in selected individuals with short stature. — Stavber L, Hovnik T, Kotnik P, Lovrečić L, Kovač J, Tesovnik T et al. European journal of endocrinology (2020)
    5. [5]
      Submicroscopic deletions at 13q32.1 cause congenital microcoria. — Fares-Taie L, Gerber S, Tawara A, Ramirez-Miranda A, Douet JY, Verdin H et al. American journal of human genetics (2015)
    6. [6]
      LIN7A depletion disrupts cerebral cortex development, contributing to intellectual disability in 12q21-deletion syndrome. — Matsumoto A, Mizuno M, Hamada N, Nozaki Y, Jimbo EF, Momoi MY et al. PloS one (2014)
    7. [7]
      Characterization of a 8q21.11 microdeletion syndrome associated with intellectual disability and a recognizable phenotype. — Palomares M, Delicado A, Mansilla E, de Torres ML, Vallespín E, Fernandez L et al. American journal of human genetics (2011)
    8. [8]
      The 3q29 microdeletion syndrome: report of three new unrelated patients and in silico "RNA binding" analysis of the 3q29 region. — Dasouki MJ, Lushington GH, Hovanes K, Casey J, Gorre M American journal of medical genetics. Part A (2011)
    9. [9]
      Microdeletion 15q13.3: a locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders. — Ben-Shachar S, Lanpher B, German JR, Qasaymeh M, Potocki L, Nagamani SC et al. Journal of medical genetics (2009)
    10. [10]
      Del(3) (p25.3) without phenotypic effect. — Knight LA, Yong MH, Tan M, Ng IS Journal of medical genetics (1995)
    11. [11]
      Familial partial trisomy of the long arm of chromosome 3 (3q). — Fear C, Briggs A Archives of disease in childhood (1979)
    12. [12]
      Genetic counseling of prenatally detected familial 15q13.2q13.3 microdeletion encompassing CHRNA7 and OTUD7A with asymptomatic carriers in the family. — Chen CP, Wu FT, Pan YT, Wu PS, Wang W Taiwanese journal of obstetrics & gynecology (2025)
    13. [13]
      Prenatal diagnosis and molecular cytogenetic characterization of mosaicism for r(10) and monosomy 10 at amniocentesis in a fetus associated with perinatal growth restriction but no gross structural abnormalities. — Chen CP, Wu FT, Pan YT, Wu PS, Lee MS, Pan CW et al. Taiwanese journal of obstetrics & gynecology (2025)
    14. [14]
      Prenatal diagnosis of familial 3p26.3p25.3 deletion in a pregnancy associated with a favorable fetal outcome and asymptomatic carrier parent and family members in three generations. — Chen CP, Wu FT, Pan YT, Wu PS, Lee MS, Wang W Taiwanese journal of obstetrics & gynecology (2024)
    15. [15]
      Mosaic distal 9p deletion or 46,XY,del(9)(p23)/46,XY at amniocentesis in a pregnancy associated with perinatal progressive decrease of the aneuploid cell line and a favorable fetal outcome. — Chen CP, Wu FT, Pan YT, Wu PS, Lee CC, Chen WL et al. Taiwanese journal of obstetrics & gynecology (2024)
    16. [16]
      Minimal Critical Region and Genes for a Typical Presentation of Langer-Giedion Syndrome. — Favilla BP, Burssed B, Yamashiro Coelho ÉM, Perez ABA, de Faria Soares MF, Meloni VA et al. Cytogenetic and genome research (2022)
    17. [17]
      Prenatal diagnosis of low-level mosaicism for a small supernumerary marker chromosome derived from chromosome 9q (9q13-q21.33) in a pregnancy with a favorable outcome, and cytogenetic discrepancy between cultured amniocytes and uncultured amniocytes. — Chen CP, Lo LM, Ko TM, Chern SR, Wu PS, Chen SW et al. Taiwanese journal of obstetrics & gynecology (2021)
    18. [18]
      Prenatal diagnosis and molecular cytogenetic characterization of three chromosomal abnormalities with favorable outcomes. — Chen Q, Xu Z, Chen G, Liu S, Xia Y Taiwanese journal of obstetrics & gynecology (2020)
    19. [19]
      Prenatal diagnosis of mosaicism for a distal 5p deletion in a single colony at amniocentesis in a pregnancy with a favorable outcome and a review of mosaic distal 5p deletion. — Chen CP, Wang LK, Chern SR, Wu PS, Chen SW, Wu FT et al. Taiwanese journal of obstetrics & gynecology (2020)
    20. [20]
      Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions in Average-Risk Pregnancies: A Cost-Effectiveness Analysis. — Xie X, Wang M, Goh ES, Ungar WJ, Little J, Carroll JC et al. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC (2020)
    21. [21]
      9q34.3 microduplications lead to neurodevelopmental disorders through EHMT1 overexpression. — Bonati MT, Castronovo C, Sironi A, Zimbalatti D, Bestetti I, Crippa M et al. Neurogenetics (2019)
    22. [22]
      Small supernumerary marker chromosomes: A legacy of trisomy rescue? — Kurtas NE, Xumerle L, Leonardelli L, Delledonne M, Brusco A, Chrzanowska K et al. Human mutation (2019)
    23. [23]
      Prenatal diagnosis of a 0.7-Mb 17p13.3 microdeletion encompassing YWHAE and CRK but not PAFAH1B1 in a fetus without ultrasound abnormalities. — Chen CP, Ko TM, Wang LK, Chern SR, Wu PS, Chen SW et al. Taiwanese journal of obstetrics & gynecology (2018)
    24. [24]
      Enabling miniaturised personalised diagnostics: from lab-on-a-chip to lab-in-a-drop. — Koo KM, Wee EJH, Wang Y, Trau M Lab on a chip (2017)
    25. [25]
      Characterization of the Phenotype Associated with Microduplication Reciprocal to NF1 Microdeletion Syndrome. — Tassano E, Giacomini T, Severino M, Gamucci A, Fiorio P, Gimelli G et al. Cytogenetic and genome research (2017)
    26. [26]
      Prenatal diagnosis and molecular cytogenetic characterization of low-level mosaic trisomy 12 at amniocentesis associated with a favorable pregnancy outcome. — Chen CP, Lin CJ, Chern SR, Wu PS, Chen YN, Chen SW et al. Taiwanese journal of obstetrics & gynecology (2017)
    27. [27]
      Prenatal diagnosis and molecular cytogenetic characterization of concomitant familial small supernumerary marker chromosome derived from chromosome 4q (4q11.1-q13.2) and 5q13.2 microdeletion with no apparent phenotypic abnormality. — Chen CP, Chern SR, Chen YN, Chen SW, Wu PS, Yang CW et al. Taiwanese journal of obstetrics & gynecology (2017)
    28. [28]
      A new familial case of microdeletion syndrome 10p15.3. — Eggert M, Müller S, Heinrich U, Mehraein Y European journal of medical genetics (2016)
    29. [29]
      Trisomy 4 mosaicism: Delineation of the phenotype. — Bouman A, van der Kevie-Kersemaekers AM, Huijsdens-van Amsterdam K, Dahhan N, Knegt L, Vansenne F et al. American journal of medical genetics. Part A (2016)
    30. [30]
      Refinement of the postnatal growth restriction locus of chromosome 5q12-13 deletion syndrome. — Holder JL, Cheung SW American journal of medical genetics. Part A (2015)
    31. [31]
      A familial interstitial 4q35 deletion with no discernible clinical effects. — Yakut S, Clarck OA, Sanhal C, Nur BG, Mendilcioglu I, Karauzum SB et al. American journal of medical genetics. Part A (2015)
    32. [32]
      17q12 microduplications: a challenge for clinicians. — Bertini V, Orsini A, Bonuccelli A, Cambi F, Del Pistoia M, Vannozzi I et al. American journal of medical genetics. Part A (2015)
    33. [33]
      Patients carrying 9q31.1-q32 deletion share common features with Cornelia de Lange Syndrome. — Cao R, Pu T, Fang S, Long F, Xie J, Xu Y et al. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology (2015)
    34. [34]
      Microdeletion 2q23.3q24.1: exploring genotype-phenotype correlations. — Milani D, Sabatini C, Manzoni FM, Ajmone PF, Rigamonti C, Malacarne M et al. Congenital anomalies (2015)
    35. [35]
      Mitotic stability of small supernumerary marker chromosomes depends on their shape and telomeres - a long term in vitro study. — Hussein SS, Kreskowski K, Ziegler M, Klein E, Hamid AB, Kosyakova N et al. Gene (2014)
    36. [36]
      Mosaic tetrasomy 9p at amniocentesis: prenatal diagnosis, molecular cytogenetic characterization, and literature review. — Chen CP, Wang LK, Chern SR, Wu PS, Chen YT, Kuo YL et al. Taiwanese journal of obstetrics & gynecology (2014)
    37. [37]
      A three-generation family with terminal microdeletion involving 5p15.33-32 due to a whole-arm 5;15 chromosomal translocation with a steady phenotype of atypical cri du chat syndrome. — Elmakky A, Carli D, Lugli L, Torelli P, Guidi B, Falcinelli C et al. European journal of medical genetics (2014)
    38. [38]
      A novel microdeletion involving the 13q31.3-q32.1 region in a patient with normal intelligence. — Valdes-Miranda JM, Soto-Alvarez JR, Toral-Lopez J, González-Huerta L, Perez-Cabrera A, Gonzalez-Monfil G et al. European journal of medical genetics (2014)
    39. [39]
      Microarray delineation of familial chromosomal imbalance with deletion 5q35 and duplication 10q25 in a child showing multiple anomalies and dysmorphism. — Masri A, Gimelli S, Hamamy H, Sloan-Béna F American journal of medical genetics. Part A (2014)
    40. [40]
      Confirmation and further delineation of the 3q26.33-3q27.2 microdeletion syndrome. — Dasouki M, Roberts J, Santiago A, Saadi I, Hovanes K European journal of medical genetics (2014)
    41. [41]
      Absence of skeletal anomalies in siblings with a maternally inherited 12q13.13-q13.2 microdeletion partially involving the HOXC gene cluster. — Peterson JF, Hartman J, Ghaloul-Gonzalez L, Surti U, Hu J American journal of medical genetics. Part A (2014)
    42. [42]
      A patient with five chromosomal rearrangements and a 2q31.1 microdeletion. — Wang T, Mao J, Liu MJ, Choy KW, Li HB, Cram DS et al. Clinica chimica acta; international journal of clinical chemistry (2014)
    43. [43]
      Clinical delineation of a patient with trisomy 12q23q24. — Bouman A, Schuitema A, Pfundt R, van de Zande G, Kleefstra T European journal of medical genetics (2013)
    44. [44]
      Mosaic 15q13.3 deletion including CHRNA7 gene in monozygotic twins. — Popovici C, Busa T, Missirian C, Milh M, Moncla A, Philip N European journal of medical genetics (2013)
    45. [45]
      First trimester diagnosis of 13q-syndrome associated with increased fetal nuchal translucency thickness. Clinical findings and systematic review. — Manolakos E, Peitsidis P, Garas A, Vetro A, Eleftheriades M, Petersen MB et al. Clinical and experimental obstetrics & gynecology (2012)
    46. [46]
      Chromosome 4q deletion syndrome: narrowing the cardiovascular critical region to 4q32.2-q34.3. — Xu W, Ahmad A, Dagenais S, Iyer RK, Innis JW American journal of medical genetics. Part A (2012)
    47. [47]
      Array-CGH study of partial trisomy 9p without mental retardation. — Bouhjar IB, Hannachi H, Zerelli SM, Labalme A, Gmidène A, Soyah N et al. American journal of medical genetics. Part A (2011)
    48. [48]
      1.3 Mb de novo deletion in chromosome band 3q29 associated with normal intelligence in a child. — Cobb W, Anderson A, Turner C, Hoffman RD, Schonberg S, Levin SW European journal of medical genetics (2010)
    49. [49]
      Characterization of an interstitial 4q32 deletion in a patient with mental retardation and a complex chromosome rearrangement. — Tzschach A, Menzel C, Erdogan F, Istifli ES, Rieger M, Ovens-Raeder A et al. American journal of medical genetics. Part A (2010)
    50. [50]
      3q29 Microdeletion: a mental retardation disorder unassociated with a recognizable phenotype in two mother-daughter pairs. — Digilio MC, Bernardini L, Mingarelli R, Capolino R, Capalbo A, Giuffrida MG et al. American journal of medical genetics. Part A (2009)
    51. [51]
      Partial chromosome deletion: a new trisomy rescue mechanism? — Vialard F, Molina-Gomes D, Quarello E, Leroy B, Ville Y, Selva J Fetal diagnosis and therapy (2009)
    52. [52]
      Isolation of yeast artificial chromosomes containing the entire transcriptional unit of the human FGF1 gene: a 720-kb contig spanning human chromosome 5q31.3-->q32. — Chiu IM, Liu Y, Payson RA Cancer genetics and cytogenetics (1998)
    53. [53]
      Mosaicism in trisomy 8: phenotype differences according to tissular repartition of normal and trisomic clones. — Miller K, Arslan-Kirchner A, Schulze B, Dudel-Neujahr A, Morlot M, Burck U et al. Annales de genetique (1997)
    54. [54]
      FISH mapping of bovine U21, U1 and U7 molecular markers to river buffalo chromosomes 3p, 5q and 5p. — Iannuzzi L, Ferretti L, Di Meo GP, Perucatti A Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology (1997)
    55. [55]
      Pure partial trisomy of the short arm of chromosome 5. — Rethoré MO, Blois MC, Peeters M, Popowski P, Pangalos C, Lejeune J Human genetics (1989)
    56. [56]
      Deletion of band 13q21 is compatible with normal phenotype. — Couturier J, Morichon-Delvallez N, Dutrillaux B Human genetics (1985)
    57. [57]
      Do numerical polymorphisms exist at the human 5 S locus? — Henderson AS, Moskowitz G, Warburton D Human genetics (1980)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG